{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:31:41Z","timestamp":1793939501816,"version":"4.8.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n All patients with newly diagnosed non\u2013small cell lung cancer (NSCLC) and colorectal cancer (CRC) should receive molecular testing to identify those who can benefit from targeted therapies. However, many patients do not receive recommended testing and targeted therapies.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare rates of molecular testing and targeted therapy use by practice type and across practices.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional study used 100% Medicare fee-for-service data from 2015 through 2019 to identify beneficiaries with new metastatic NSCLC or CRC diagnoses receiving systemic therapy and to assign patients to oncology practices. Hierarchical linear models were used to characterize variation by practice type and across practices. Data analysis was conducted from June 2019 to October 2022.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Oncology practice providing care.<\/jats:p>\n <\/jats:sec>\n \n Outcomes<\/jats:title>\n Primary outcomes were rates of molecular testing and targeted therapy use for patients with NSCLC and CRC. Secondary outcomes were rates of multigene testing for NSCLC and CRC.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There were 106\u202f228 Medicare beneficiaries with incident NSCLC (31\u202f521 [29.7%] aged 65-69 years; 50\u202f348 [47.4%] female patients; 2269 [2.1%] Asian, 8282 [7.8%] Black, and 91\u202f215 [85.9%] White patients) and 39\u202f512 beneficiaries with incident CRC (14\u202f045 [35.5%] aged 65-69 years; 17\u202f518 [44.3%] female patients; 896 [2.3%] Asian, 3521 [8.9%] Black, and 32\u202f753 [82.9%] White patients) between 2015 and 2019. Among these beneficiaries, 18\u202f435 (12.9%) were treated at National Cancer Institute (NCI)\u2013designated centers, 8187 (5.6%) were treated at other academic centers, and 94\u202f329 (64.7%) were treated at independent oncology practices. Molecular testing rates increased from 74% to 85% for NSCLC and 45% to 65% for CRC. First-line targeted therapy use decreased from 12% to 8% among patients with NSCLC and was constant at 5% for patients with CRC. For NSCLC, molecular testing rates were similar across practice types while rates of multigene panel use (13.2%) and targeted therapy use (16.6%) were highest at NCI-designated cancer centers. For CRC, molecular testing rates were 3.8 (95% CI: 1.2-6.5), 3.3 (95% CI, 0.4-6.1), and 12.2 (95% CI, 9.1-15.3) percentage points lower at hospital-owned practices, large independent practices, and small independent practices, respectively. Rates of targeted therapy use for CRC were similar across practice types. After adjusting for patient characteristics, there was moderate variation in molecular testing and targeted therapy use across oncology practices.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cross-sectional study of Medicare beneficiaries, molecular testing rates for NSCLC and CRC increased in recent years but remained lower than recommended levels. Rates of targeted therapy use decreased for NSCLC and remained stable for CRC. Variation across practices suggests that where a patient was treated may have affected access to recommended testing and efficacious treatments.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.10809","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T11:34:07Z","timestamp":1682681647000},"page":"e2310809","source":"Crossref","is-referenced-by-count":38,"title":["Practice-Level Variation in Molecular Testing and Use of Targeted Therapy for Patients With Non\u2013Small Cell Lung Cancer and Colorectal Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Thomas J.","family":"Roberts","sequence":"first","affiliation":[{"name":"Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"Kehl","sequence":"additional","affiliation":[{"name":"Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel A.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette","family":"Sholl","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi A.","family":"Wright","sequence":"additional","affiliation":[{"name":"Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Landrum","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Keating","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of General Internal Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"10299","key":"zoi230341r1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer.","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"zoi230341r2","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer.","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi230341r3","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"zoi230341r4","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer.","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi230341r5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"7407","key":"zoi230341r6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer.","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"issue":"19","key":"zoi230341r7","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-19-0899","article-title":"Comprehensive genomic landscapes in early and later onset colorectal cancer.","volume":"25","author":"Lieu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"zoi230341r9","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1200\/JCO.2009.21.9170","article-title":"American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.","volume":"27","author":"Allegra","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi230341r11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.","volume":"20","author":"Lindeman","year":"2018","journal-title":"J Mol Diagn"},{"key":"zoi230341r12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1200\/PO.20.00359","article-title":"Uptake of KRAS testing and anti-EGFR antibody use for colorectal cancer in the VA.","volume":"5","author":"Becker","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"15","key":"zoi230341r13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e18119","article-title":"Biomarker testing, treatment (Tx) and survival outcomes in Medicaid compared to commercially insured (CI) patients with advanced NSCLC (aNSCLC).","volume":"37","author":"Yim","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi230341r14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/jnci\/djy202","article-title":"Race, poverty, and initial implementation of precision medicine for lung cancer.","volume":"111","author":"Kehl","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"zoi230341r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00159","article-title":"ALK testing trends and patterns among community practices in the United States.","volume":"2","author":"Illei","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"zoi230341r16","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1016\/j.cllc.2016.11.002","article-title":"Utilization patterns and trends in epidermal growth factor receptor (EGFR) mutation testing among patients with newly diagnosed metastatic lung cancer.","volume":"18","author":"Shen","year":"2017","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"zoi230341r17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2021.7083","article-title":"Associations between Medicaid insurance, biomarker testing, and outcomes in patients with advanced NSCLC.","volume":"20","author":"Gross","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"zoi230341r18","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00274","article-title":"Genomic profiling for KRAS, NRAS, BRAF, microsatellite instability, and mismatch repair deficiency among patients with metastatic colon cancer.","volume":"3","author":"Gutierrez","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"zoi230341r19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2217\/pme-2019-0107","article-title":"Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy.","volume":"17","author":"Freml","year":"2020","journal-title":"Per Med"},{"issue":"5","key":"zoi230341r20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2018.9824","article-title":"Association of broad-based genomic sequencing with survival among patients with advanced non-small cell lung cancer in the community oncology setting.","volume":"320","author":"Presley","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"zoi230341r21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12885-018-4190-3","article-title":"Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.","volume":"18","author":"Lynch","year":"2018","journal-title":"BMC Cancer"},{"key":"zoi230341r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00156","article-title":"Classifying stage IV lung cancer from health care claims: a comparison of multiple analytic approaches.","volume":"3","author":"Brooks","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"5","key":"zoi230341r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8055","article-title":"Assessment of patient attribution to care from medical oncologists, surgeons, or radiation oncologists after newly diagnosed cancer.","volume":"4","author":"Gondi","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi230341r25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/MLR.0000000000000840","article-title":"Diffusion of bevacizumab across oncology practices: an observational study.","volume":"56","author":"Keating","year":"2018","journal-title":"Med Care"},{"issue":"12","key":"zoi230341r27","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1001\/jamainternmed.2015.4610","article-title":"Association of financial integration between physicians and hospitals with commercial health care prices.","volume":"175","author":"Neprash","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"12","key":"zoi230341r29","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data.","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"zoi230341r33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1200\/JGO.2015.002105","article-title":"EGFR mutations in Latinos from the United States and Latin America.","volume":"2","author":"Lopez-Chavez","year":"2016","journal-title":"J Glob Oncol"},{"issue":"3","key":"zoi230341r34","doi-asserted-by":"publisher","first-page":"S443","DOI":"10.1016\/j.jtho.2021.01.751","article-title":"P37.04 EGFR mutations in US Hispanics with lung adenocarcinoma are common and portend a worse prognosis.","volume":"16","author":"Villena-Vargas","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"7511","key":"zoi230341r35","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma.","volume":"511","author":"Collisson","year":"2014","journal-title":"Nature"},{"issue":"19","key":"zoi230341r36","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi230341r37","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi230341r38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality.","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi230341r39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/onco.13705","article-title":"FOLFOXIRI plus bevacizumab versus FOLFOX plus panitumumab for metastatic left-sided RAS\/BRAF wild-type colorectal cancer: which \u201cside\u201d are you on?","volume":"26","author":"Yu","year":"2021","journal-title":"Oncologist"},{"issue":"11","key":"zoi230341r40","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"issue":"40","key":"zoi230341r41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1200\/EDBK_280795","article-title":"Checkpoint blockade in lung cancer with driver mutation: choose the road wisely.","volume":"40","author":"Calles","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"zoi230341r42","doi-asserted-by":"publisher","first-page":"e663","DOI":"10.1016\/S2666-7568(21)00179-3","article-title":"Is cancer biology different in older patients?","volume":"2","author":"Van Herck","year":"2021","journal-title":"Lancet Healthy Longev"},{"issue":"5","key":"zoi230341r43","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/1055-9965.EPI-18-0917","article-title":"Disparities and trends in genetic testing and erlotinib treatment among metastatic non-small cell lung cancer patients.","volume":"28","author":"Palazzo","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"zoi230341r44","doi-asserted-by":"publisher","first-page":"e1774","DOI":"10.1200\/OP.20.01023","article-title":"Association between Medicare\u2019s national coverage determination and utilization of next-generation sequencing.","volume":"17","author":"Sheinson","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"zoi230341r8","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. June 15, 2021. Accessed September 15, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"zoi230341r10","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Colon cancer. September 10, 2021. Accessed September 15, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf"},{"key":"zoi230341r22","unstructured":"An overview of the Medicare Part D prescription drug benefit. Kaiser Family Foundation. October 19, 2022. Accessed February 22, 2023. https:\/\/www.kff.org\/medicare\/fact-sheet\/an-overview-of-the-medicare-part-d-prescription-drug-benefit\/"},{"key":"zoi230341r26","unstructured":"National Cancer Institute. NCI-designated cancer centers. April 5, 2012. Accessed October 29, 2021. https:\/\/www.cancer.gov\/research\/infrastructure\/cancer-centers"},{"key":"zoi230341r28","unstructured":"ResDAC. Research Triangle Institute (RTI) race code. Accessed October 7, 2021. https:\/\/resdac.org\/cms-data\/variables\/research-triangle-institute-rti-race-code"},{"key":"zoi230341r30","unstructured":"Rural Health Research Center. Rural-Urban Commuting Area Codes (RUCAs). Accessed October 7, 2021. https:\/\/depts.washington.edu\/uwruca\/"},{"key":"zoi230341r31","unstructured":"US Census Bureau. American Community Survey Data. Accessed October 7, 2021. https:\/\/www.census.gov\/programs-surveys\/acs\/data.html"},{"key":"zoi230341r32","unstructured":"US Food and Drug Administration. Erlotinib (Tarceva). November 3, 2018. Accessed October 21, 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/erlotinib-tarceva"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2804255\/roberts_2023_oi_230341_1681936714.6605.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T11:34:12Z","timestamp":1682681652000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2804255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.10809","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]}}}